SCHEMBL1863181

SCHEMBL1863181

O[C@H]1[CH]CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL218013 1.00
SCHEMBL1864723 1.00
SCHEMBL5170595 0.97 TSHR (0.35)
SCHEMBL1144431 0.97
SCHEMBL9359194 0.97 TSHR (0.35)
SCHEMBL2535651 0.97
SCHEMBL9122289 0.97 TSHR (0.35)
SCHEMBL11067279 0.97 TSHR (0.35)
SCHEMBL21222731 0.97
SCHEMBL11062282 0.97 TSHR (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112313234-B Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists 百济神州有限公司 2022-04-29 CN claimed
US-20210198267-A1 PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST BEONE MEDICINES I GMBH (CH) 2021-07-01 US claimed
CN-112313234-A Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists 百济神州有限公司 2021-02-02 CN claimed
EP-1432691-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP claimed
US-20040063691-A1 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-04-01 US claimed
WO-2003040107-A1 IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2003-05-15 WO claimed
EP-4217354-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2023-08-02 EP disclosed
CN-112313234-B Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists 百济神州有限公司 2022-04-29 CN disclosed
US-20210198267-A1 PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST BEONE MEDICINES I GMBH (CH) 2021-07-01 US disclosed
CN-112313234-A Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists 百济神州有限公司 2021-02-02 CN disclosed
CN-108026067-B 6-amino-quinoline-3-carbonitriles as COT modulators 吉利德科学公司 2021-01-12 CN disclosed
EP-3319955-B1 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS GILEAD SCIENCES INC (US) 2020-11-25 EP disclosed
CN-111212840-A Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor 苏文生命科学有限公司 2020-05-29 CN disclosed
EP-1326853-B1 THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER LAMBERT CO (US) 2005-09-07 EP disclosed
US-20050020532-A1 Partial and full agonists of A1 adenosine receptors GILEAD PALO ALTO, INC. 2005-01-27 US disclosed
WO-2004007519-A1 PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS CV THERAPEUTICS, INC. (US) 2004-01-22 WO disclosed
US-20030050275-A1 Partial and full agonists of A1 adenosine receptors GILEAD PALO ALTO, INC. 2003-03-13 US disclosed
US-5480668-A N-substituted derivatives of aspartame useful as sweetening agents NOFRE CLAUDE (FR) 1996-01-02 US disclosed
EP-0669935-A1 COMPOUNDS USEFUL AS SWEETENING AGENTS AND PROCESS FOR THEIR PREPARATION. NOFRE CLAUDE (FR) 1995-09-06 EP disclosed
WO-1994011391-A1 COMPOUNDS USEFUL AS SWEETENING AGENTS AND PROCESS FOR THEIR PREPARATION NOFRE CLAUDE (FR) 1994-05-26 WO disclosed